



June 24, 2021

BSE Limited

Code: 532321

1st Floor, P J Towers,

Dalal Street,

Mumbai-400001

National Stock Exchange of India Limited

Code: Cadilahc

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated June 24, 2021 titled "Zydus Cadila receives tentative approval from USFDA for Fingolimod Capsules .25mg".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,


Yours faithfully,

For, CADILA HEALTHCARE LIMITED

DHAVAL N. SÓNI

COMPANY SECRETARY

Encl.: As above



Zydus Cadila receives tentative approval from USFDA for Fingolimod Capsules .25mg

Ahmedabad, India, 24 June, 2021

Zydus Cadila has received tentative approval from the USFDA to market Fingolimod Capsules in the strength of .25 mg (US RLD: Gilenya® Capsules). Earlier, in October 2020, the group was granted approval to market Fingolimod Capsules in the strength of .5mg. Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

CIN: L24230GJ1995PLC025878